Pulmonary hypertension, family and environment

Journal of Human Hypertension

Volumn 11, Issue 9, 1997, Pages 559-561

  Gonzalez, A M ^a   Smith, A ^a   Emery, C ^a   Higenbottam, T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Dexfenfluramine; Familial pulmonary hypertension; Fawn hooded rat

Indexed keywords

ANOREXIGENIC AGENT; BIOGENIC AMINE; DEXFENFLURAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHROMOSOME 2; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FAMILY; GENE LOCUS; HUMAN; HYPOXIA; NONHUMAN; PULMONARY HYPERTENSION; QUALITY OF LIFE; RAT; RISK; SHORT SURVEY; STORAGE;

EID: 0030725677     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000488     Document Type: Short Survey

References (34)

1. Penketh ARL, Higenbottam TW, Hakim M, Wallwork J. Heart and lung transplantation in patients with end stage lung disease. Br Med J 1987; 295: 311-314.
2. Barst RJ et al. A comparison of continuous epoprosterol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
3. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension: I Clinical and haemodynamism study. Am J Med 1951; 11: 686-701.
4. Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension including pharmacological observations on pulmonary vascular resistance. Bull NY Acad Med 1954; 30: 195-207.
5. Loyd JE et al. Heterogeneity of pathological lesions in familial primary pulmonary hypertension. Am Rev Respir Dis 1988; 138: 952-957.
6. Rich S et al. Primary pulmonary hypertension: A National Prospective Study. Ann Inter Med 1987; 107: 216-223.
7. Loyd JE et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Resp Crit Care Med 1995; 152: 93-97.
8. Loyd JE, Rumm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 1984; 129: 194-197.
9. Nichols WC et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q 31-32. Nat Genet 1997; 15: 277-280.
10. Girard TJ et al. Structure of the human lipoprotein-associated coagulation inhibitor gene. Intro/exon gene organisation and localization of the gene to chromosome 2. J Biol Chem 1991; 266: 5036-5041.
11. Collins RJ, Hardwick H, Jeffery H. Perinatal cocaine intoxication. Med J Aust 1989; 150: 331-332.
12. Masi AT. Pulmonary hypertension and oral contraceptive usage. Chest 1976; 69: 451-453.
13. Legoux B et al. Pulmonary hypertension and HIV infection. Am J Med 1990; 89: 122.
14. Gurtner HJP. Aminorex and pulmonary hypertension. Cor Vasa 1985; 27: 160-171.
15. Brenot F et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537-541.
16. Abenhaim L et al. for the International Primary Pulmonary Hypertension Study Group 1996. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
17. Naeije R et al. Effect of dexfenfluramine on hypoxic pulmonary vasoconstrictive and embolic pulmonary hypertension in dogs. Am J Resp Crit Care Med 1995; 151: 682-692.
18. Michelakis ED et al: Anorexic agents inhibit potassium currents in pulmonary artery smooth muscle cells. Am J Resp Crit Care Med 1995; 151 (Suppl A): 725 (abstract).
19. Geller E, Ritsco ER, Freeman BJ, Yurlev A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms of three autistic boys. N Engl J Med 1980; 307: 165-169.
20. Herve P et al. Increased plasma serotonin in primary pulmonary hypertension.. Am J Med 1995; 99: 249-254.
21. Rattray M et al. Chronic d-fenfluramine decreases serotonin transporter messenger RNA expression in dorsal raphe nucleus. Eur J Pharmacol 1994; 268: 439-442.
22. MRC Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; i: 681-685.
23. Timms RM, Ichaja FU, Williams GN. Haemodynamic response to oxygen therapy in chronic obstructive lung disease. Annal Int Med 1985; 102: 28-36.
24. Bowyers JJ et al. Effect of LTOT and home in children with pulmonary vascular disease. Br Heart J 1986; 55: 385-390.
25. Harris P. Evolution, hypoxia and high altitude. In: Aspects of hypoxia by Health D. Liverpool University Press, 1986.
26. Niermeyer S et al. Arterial oxygen saturation in Tibetan and Han infants born in Lhasa, Tibet. N Engl J Med 1995; 333: 1248-1252.
27. Niermeyer S et al. Arterial oxygenation and pulmonary arterial pressure in healthy neonates and infants at high altitude. J Pediatr 1993; 123: 767-772.
28. Brown DM et al. Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nat Genet 1996; 12: 44-51.
29. Stelzner TJ et al. Increased endothelin-1 expression in rats with pulmonary hypertension. Am J Physiol (Lung Cell Mol Physiol 6) 1992; 262: L614-L620.
30. Zamora M et al. Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats. Am J Physiol (Lung Cell Mol Physiol 14) 1996; 270: L101-L109.
31. Frankel S et al. Birthweight, body mass index in middle age and incidence of coronary heart disease. Lancet 1996; 348: 1478-1480.
32. Stein CE et al. Fetal growth and coronary disease in South India. Lancet 1996; 348: 1269-1273.
33. Hempl V, Hinget J. Perinatal hypoxia increases hypoxic pulmonary vasoconstriction in adult rats recovering from chronic hypoxia. Am Rev Resp Dis 1990; 142: 619-624.
34. Smith APL, Jones RD, Emery CJ, Higenbottam TW. Decreased nitric oxide synthase (NOS III) mRNA in lungs from rats exposed to perinatal chronic hypoxia. Am J Resp Crit Care Med 1997; 155(4): A241 (Abstract).